• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Basic and clinical Research for Caveolin as a therapeutic target for urogenital cancer

Research Project

Project/Area Number 13671652
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Urology
Research InstitutionOkayama University

Principal Investigator

NASU Yasutomo  Okayama University Hospital, Professor, 医学部附属病院, 講師 (20237572)

Co-Investigator(Kenkyū-buntansha) ARATA Ryouji  Okayama University Hospital, Lecturer, 医学部附属病院, 助手 (00314675)
TUSHIMA Tomoyasu  Okayama University, Graduate School of Medicine and Dentistry, Associate Professor, 大学院・医歯学総合研究科, 助教授 (20135990)
Project Period (FY) 2001 – 2002
Project Status Completed (Fiscal Year 2002)
Budget Amount *help
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2002: ¥1,600,000 (Direct Cost: ¥1,600,000)
Fiscal Year 2001: ¥1,900,000 (Direct Cost: ¥1,900,000)
KeywordsCaveolin / androgen / baladder cancer / prostate cancer / MDR / MRP
Research Abstract

Purpose of this research is to elucidate the basic and clinical implication. of caveolin as a therapeutic molecular target for urogenital cancer. We have highlighted the mechanistic analysis of the formation of multi drug resistance for anti-cancer drugs. Expression study of caveolin, multidrug resistance related molecules (MDR, MRP) was performed using cultured cells and clinical samples. Caveolin expression was also analyzed morphologically using transmission electron microscope as a form of caveolae.
1)Bladder cancer cell lines
Parent and induced Adriamycin (ADM) resistant bladder cell lines (T-24 vs T-24/ADM and KK-47 vs KK-47/ADM) were analyzed. Caveolin expression decreased in T-24/ADM compared to T-24 but increased in KK-47/ADM compared to KK-47. Expression level of caveolin protein positively correlated with the number of caveolae detected by TEM. MDR was positive in KK-47/AD. MRP was positive in T-24/ADM and KK-47/ADM. Expression of MDR was positively correlated with caveolin in the process of drug resistance formation.
2)Clinical sample of bladder cancer
Clinical samples were obtained from the patients who showed resistance or recurrence to conventional anticancer drug treatment including ADM. No correlation was observed among the protein expression of caveolin, MDR and MRP
3)Prostate cancer cell lines
Human prostate cancer cell lines (PC-3, DU-145, LNCap) were analyzed with the same methods used in the analysis of the bladder cancer, No correlation was observed among the protein expression of cave olin, MDR and MRP

Report

(3 results)
  • 2002 Annual Research Report   Final Research Report Summary
  • 2001 Annual Research Report
  • Research Products

    (22 results)

All Other

All Publications (22 results)

  • [Publications] 那須保友: "前立腺癌のアンドロゲン依存性とカベオリン"Urological Review. 3. 2-5 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Li L: "Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells."Cancer Res. 61. 4386-4392 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Kraaji R.: "Validation of transrectal ultrasonographic volumetry for orthotopic prostate tumours in mice"Lab Anim. 36(2). 165-172 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Ebara S: "Gene therapy for prostate cancer : toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters."Prostate Cancer Prostatic Dis. 5(4). 316-325 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] 那須保友: "前立腺癌の遺伝子治療-臨床研究における最近の動向"医学のあゆみ. 203(5). 323-327 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] 那須保友: "前立腺癌の遺伝子診断と遺伝子治療"日本臨牀. 60(Suppl 1). 28-32 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Y, Nasu: "Androgen dependency and caveolin"Urological Review. 3. 2-5 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] L, Li: "Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells."Cancer Res.. 61. 4386-4392 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Kraaji R: "Validation of transrectal ultrasonographic volumetry for orthotopic prostate tumours in mice"Lab Anim.. 36(2). 165-172 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] S, Ebara: "Gene therapy for prostate cancer : toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters."Prostate Cancer Prostatic Diseases. 5(4). 316-325 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Y, Nasu: "Current status and future prospect of prostate cancer gene therapy"Igakuno Ayumi. 203(5). 323-327 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Y, Nasu: "Molecular Diaganosis sand Gene Therapy for Prostate Cancer"Nippon Rinsho. 60(supp1). 28-32 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Kraaji R.: "Validation of transrectal ultrasonographic volumetry for orthotopic prostate tumours in mice"Lab Anim. 36(2). 165-172 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Ebara S: "Gene therapy for prostate cancer : toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters"Prostate Cancer Prostatic Dis. 5(4). 316-325 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] 那須保友, 公文裕巳: "前立腺癌遺伝子治療の現状と展望"岡山医学会雑誌. 114. 173-177 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] 那須保友: "前立腺癌の遺伝子治療-臨床研究における最近の動向"医学のあゆみ. 203(5). 323-327 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] 那須保友: "前立腺癌の遺伝子診断と遺伝子治療"日本臨牀. 60(Suppl 11). 28-32 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] 那須保友: "前立腺癌のアンドロゲン依存性とカベオリン"Urological Review. 3(3). 2-5 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] 那須保友: "泌尿生殖器におけるバイオマーカーの新展開-前立腺癌のバイオマーカーの現況と展望"臨床泌尿器科. 55(7). 539-544 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Likun Li: "Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells"Cancer Research. 61. 4386-4392 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Tsushima T: "Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist"Urologia Internationalis. 66. 135-139 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Nasu Y: "Combination gene therapy with adenoviral vector-mediated HSV-tk+ GCV and IL-12 in an orthotopic mouse model for prostate cancer"Prostate Cancer and Prostatic Diseases. 4. 44-55 (2001)

    • Related Report
      2001 Annual Research Report

URL: 

Published: 2001-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi